Following the WHO supplier qualification certification of Gonglin South Medicine Artemisia Artemisia Artemishane injection，Another member of Chongqing Pharmaceutical Friends Pharmaceutical has recently passed the GMP certification of the Canadian Ministry of Health
　　

Strategies to steadily advance from the dream of unreachable to the same time，Chinese pharmaceutical companies are accelerating their internationalization steps。

In the successor of Guilin South Medicine Artemisia Artemishane injection, the World Health Organization (WHO) supplier qualification certification is not long，Another member of Fosun Pharmaceutical Group -Chongqing Pharmaceutical Friends Pharmaceutical recently passed the GMP certification of the Canadian Ministry of Health，This is also the first transcript that Yaoyou Pharmaceuticals has surrendered since implementing the internationalization strategy。

Stake Sports Bettingstake online sports bettingDested，In recent years, Fosun Pharmaceutical has been actively promoting internationalization，aiming at the global mainstream market，Herteo uses the Chinese market、Advantages of resources and costs，Go to the global road that combines Chinese creation and Chinese manufacturing。
　　

Tao Canada

　　
"Through the Canadian GMP certification, we will receive valuable experience for us to receive certification inspections from other Western countries in the next step，It laid a solid foundation for the international development of medicine friends，It is the first battle for the drug friends to overcome the international drug market technology barriers。"Wang Fan, president of Chongqing Pharmaceutical Friends Pharmaceutical。It is reported，Pharmaceuticals Pharmaceutical is the first prescription agent in China to pass the GMP certification of the Ministry of Health of Canada。At the same time，Canada as the European Union、Australia、New Zealand reached a country with GMP mutual recognition agreement，It means that Chongqing Pharmaceutical Friends crossed the first threshold for entering the market in developed countries。Wang Fan revealed，Canadian GMP authentication is for varieties，This time they passed a mitigation tablet，"After passing it，We are starting to register and declare，officially entered the Canadian market at the end of next year。”

"This is the first step we take，The next goal is the European Union and the United States。"Wang Fan admits，The Canadian market with more than 20 million people is not very big，The final goal of the company is Europe and the United States。Facts，Chongqing Pharmaceutical Friends Pharmaceuticals stake betting appstake sports betting apphad submitted the first ANA project registration application for the first Hydrochloride product product for the US FDA。

Vice President of Fosun Medicine and General Manager Cui Zhiping said: "Although China has always occupied an advantage in the exit of raw materials，But the huge space of generic drug preparations in the mainstream pharmaceutical market is even more challenging and attractive。Current，Only the United States、Europe、Japan's three regions occupy 85%of the global pharmaceutical market。To develop international business，We are increasing the variety，It also breaks the barriers of the region，Enter these markets as soon as possible。"" In terms of drug manufacturing，Fosun Pharmaceutical Requirements Requirements to strengthen GMP management，Investment and transformation of existing enterprises，Gradually strive to work with the international CGMP standard。It is understood，Current，About 30%of the sales revenue of Fosun Pharmaceutical and Pharmaceutical Industry comes from product export。

　　
Artemisinin varieties powerful

　　
Guilin South Medicine, a subsidiary of Fosun Pharmaceutical, learned from WHO a few days ago，Guilin South Medicine Artemisia Artemisha Elly Entry Workshop GMP on-site inspection has complied with the WHO-GMP specification。November 5，The official website of WHO has officially included the injection of artemisin produced by Guilin South Pharmaceuticals in the PQ drug list。Fosun Pharmaceutical-Su Li, vice president of Guilin South Medicine, said: "This will be conducive to the further improvement of Guilin South Pharmaceutical's influence，Accelerate stake betting appstake online sports bettingthe company's product development and international market expansion。"Current，Guilin South Medicine Artemisia Artemishane injection production capacity is 6 million supports/year，2009 capacity utilization rate is 33%。Facts，Emperor Artemisia annua products of Nan medicine before Guilin have been exported to nearly 50 countries，An important promoter of becoming Fosun Pharmaceutical Export Strategy。

But，The ambition of Fosun Pharmaceutical is obviously not just the industrial level of "exporting more products to overseas"，It also focuses on having something in the overseas capital market。Chairman of Fosun Pharmaceutical Chen Qiyu said: "，Fosun Pharmaceutical always insists on walking two legs。On the one hand, it is in the industrial market，Actively seek cooperative mergers and acquisitions opportunities，Use the different needs of technology and products with two markets，Introduce the other good technology of the other party，Through our research and development of new drugs in the Chinese market、Registration、Approval、Production and other market -oriented chains are good at rapid industrialization，In foreign countries, the cooperation partner can use the cooperation party to be familiar with and understand the international standard system，and perfect marketing network，Selling the product to the international market。Exchange through two markets，Integrated resources，Walk out of the road to differentiation with Chinese pharmaceutical companies。The second aspect is to cut in through the overseas capital market，Help us expand international vision，In terms of positioning of the entire internationalization My stake betting appstake sports betting appstrategy，We still have to be based on China's local market，At the same time, actively open up the United States, the world's largest single market。"" For enterprises investing mergers and acquisitions，Fosun Pharmaceutical is more optimistic about those in Europe, America and Japan，Have the ability to grow rapidly，R & D and marketing capabilities is strong or in product、Technology、Team has special features，。